An antibody against BTN1A1 (hSTC810) is already being studied in clinical trials (NCT05231746) [55] and if efficacious, BTN1A1 could represent a novel immunotherapy target in BRAF-mutated PM-CRC. This evidence concerns the gene BRAF and colorectal carcinoma.